Despite heavy demand for its weight-loss and diabetes treatments, limited supply hobbled Eli Lilly's fourth-quarter sales.

Eli Lilly ( LLY 3.89%) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom lines in ...

Lilly is projecting between $58 billion and $61 billion in sales, which is mostly higher than the $58.4 billion that analysts expected. In its press release, it didn't provide specific guidance ...

Shares of Eli Lilly & Co. were headed for their worst day ... citing slower-than-expected growth in sales of its diabetes and weight-loss drugs. “While the U.S. incretin market grew 45% compared ...

Mounjaro and Zepbound sales disappoint, and Eli Lilly’s stock is dropping Eli Lilly’s stock was set to suffer its worst day in four years after sales of diabetes and obesity drugs Mounjaro and ...

Last July, Lilly's Alzheimer's disease candidate Kisunla earned approval from the FDA to treat Alzheimer's disease. Intended for early-stage patients with mild cognitive impairment, annual sales ...

In the first half of 2024, it seemed Eli Lilly (NYSE ... presentation at the annual JPMorgan Healthcare conference. On Jan. 14, CEO David Ricks told investors that 2024 sales would come in ...

The coveted Disneyland Magic Key annual passes go on sale next week. Should you buy one? Many or all of the products on this page are from partners who compensate us when you click to or take an ...

A Trump-bashing, Pulitzer Prize-winning political cartoonist — whose illustrations have been published by the Washington Post, New Yorker and Los Angeles Times — was arrested for possession of ...

Eli Lilly and Company LLY dropped 6.6% in the Jan. 14 trading session after slashing its revenue guidance for the fourth quarter and fiscal 2024, citing lower-than-expected sales for its weight ...

Eli Lilly shares climbed 32% last year but have slumped more than 16% since October after the company reported third quarter sales of the two drugs below Wall Street’s expectations, prompting ...